In this video, Erica Mayer, MD, MPH, from Dana-Farber Cancer Institute in Boston, MA, reviews results from the EMBER-3 trial exploring imlunestrant, with and without abemaciclib, as a novel, all-oral, chemotherapy-free therapy in the treatment of patients with estrogen receptor–positive/HER2-negative breast cancer. Read More ›

Zongertinib shows promising efficacy in patients with brain metastases in pretreated HER2-mutant non−small cell lung cancer Read More ›

Sevabertinib demonstrates promising efficacy and manageable safety in pretreated HER2-mutant non−small cell lung cancer (NSCLC) patients Read More ›

In this video, Dr Sara Tolaney underscores the positive overall survival outcomes from the monarchE trial, reinforcing the impact of adjuvant abemaciclib plus endocrine therapy in high-risk, hormone receptor (HR)-positive/HER2-negative early breast cancer, while also noting the sustained 5-year benefits observed with ribociclib and nonsteroidal aromatase inhibitors in the NATALEE trial. Read More ›

Patient-reported outcomes from the Beamion LUNG-1 trial showed sustained improvements in physical functioning and symptom burden, with low side effect severity, supporting zongertinib’s potential in advanced NSCLC. Read More ›

The SOHO-01 trial highlights the manageable safety and promising efficacy of sevabertinib (BAY 2927088) in patients with pretreated or untreated HER2-mutant NSCLC. Read More ›

The Beamion LUNG-1 study explored zongertinib as a promising HER2-targeted therapy for advanced or metastatic non–small cell lung cancer (NSCLC). Read More ›

SKYSCRAPER-01 evaluated the combination of tiragolumab and atezolizumab and suggests potential antitumor activity in NSCLC. Read More ›

EMBER-3 trial findings position imlunestrant monotherapy or in combination with abemaciclib as a promising, safe and effective oral therapeutic option for treating estrogen receptor (ER)-positive, HER2-negative advanced breast cancer. Read More ›

Elacestrant in combination with ribociclib or everolimus demonstrates promising efficacy and manageable safety in patients with estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer who experienced disease progression after endocrine therapy plus CDK4/6 inhibitors, Read More ›